DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,145,821 | +135834.6% | 129,568 | +31.5% | 3.50% | +139.8% |
| Q2 2023 | $23,648 | -99.9% | 98,532 | 0.0% | 1.46% | -9.3% |
| Q1 2023 | $24,834,005 | -17.2% | 98,532 | -12.8% | 1.61% | -19.3% |
| Q4 2022 | $29,995,645 | -99.9% | 113,012 | +9.9% | 2.00% | +10.6% |
| Q3 2022 | $26,069,969,000 | 0.0% | 102,832 | 0.0% | 1.80% | 0.0% |
| Q2 2022 | $26,069,969,000 | +133935.8% | 102,832 | +55.1% | 1.80% | +71.6% |
| Q1 2022 | $19,450,000 | +32.7% | 66,306 | +48.8% | 1.05% | +51.7% |
| Q4 2021 | $14,656,000 | +9.7% | 44,546 | +1.5% | 0.69% | +1.8% |
| Q3 2021 | $13,360,000 | -34.5% | 43,883 | -42.3% | 0.68% | -35.5% |
| Q2 2021 | $20,398,000 | +16.4% | 76,009 | -2.4% | 1.06% | +4.0% |
| Q1 2021 | $17,527,000 | +28.8% | 77,871 | +27.1% | 1.01% | +26.6% |
| Q4 2020 | $13,610,000 | +182.4% | 61,267 | +75.9% | 0.80% | +65.2% |
| Q1 2020 | $4,820,000 | -17.8% | 34,825 | -8.8% | 0.48% | +12.5% |
| Q4 2019 | $5,863,000 | +39.4% | 38,202 | +31.2% | 0.43% | +27.5% |
| Q3 2019 | $4,207,000 | – | 29,128 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |